NEURORADIOLOGY / GUIDELINES / RECOMMENDATIONS
 
KEYWORDS
TOPICS
ABSTRACT
Neurofibromatosis type 1 (NF1) is a genetically determined disorder with a complex clinical picture, including disorders of many systems and organs, that predisposes to the development of various cancers. Approximately 10-30% of patients with NF1 develop plexiform neurofibromas (PN), non-malignant tumours growing along the nerves, tending to infiltrate nerves and nerve plexuses, and may grow into internal organs, the spinal canal, and middle ear, deforming bones and various regions of the body. Magnetic resonance imaging (MRI) plays a key role in the management of individuals during the course of PN, as a screening tool at baseline, for surveillance (in individuals with known PN), to evaluate treatment response, and for preoperative assessment for surgical planning. The practical recommendations presented in this article aim to standardise the protocol for MRI examination of PN in the course of NF1 for the purpose of treatment in a clinical program in Poland. The protocol, covering volumetric MRI examination, imaging schedule, determination of the target change, the technique for measuring the volume of lesions, and suspected malignant transformation, is intended to be the minimum set of MRI sequences and views that must be included in every examination of these patients.
REFERENCES (10)
1.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23: 1506-1513.
 
2.
Cannon A, Chen MJ, Li P, Boyd KP, Theos A, Redden DT, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis 2018; 13: 31. DOI: 10.1186/s13023-018-0772-z.
 
3.
Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH. Malignant peripheral nerve sheath tumors – a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management. Children (Basel) 2022; 9: 38. DOI: 10.3390/children9010038.
 
4.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020; 382: 1430-1442.
 
5.
Program lekowy B.155 „Leczenie chorych z nerwiakowłókniakami splotowatymi w przebiegu neurofibromatozy typu 1 (NF1)”. Ministerstwo Zdrowia; 2024.
 
6.
Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol 2022; 24: 1827-1844.
 
7.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology 2016; 87: S31-S39.
 
8.
Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine 2023; 56: 101818. DOI: 10.1016/j.eclinm.2022.101818.
 
9.
Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013; 81: S33-S40.
 
10.
Liu J, Huang JN, Wang MH, Ni ZY, Jiang WH, Chung M, et al. Image-based differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Front Oncol 2022; 12: 898971. DOI: 10.3389/fonc.2022.898971.
 
Journals System - logo
Scroll to top